ReviewFrontiers in cardiovascular medicine2026
The use of direct oral anticoagulants in children with congenital and acquired heart disease.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Direct oral anticoagulants (DOACs), including the direct thrombin inhibitor, dabigatran, and factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban), represent a significant advancement in pediatric anticoagulation therapy. Following U.S. FDA approvals for dabigatran and rivaroxaban in 2021 and apixaban in 2025, DOACs are now available for venous thromboembolism (VTE) prevention and treatment in pediatric patients; edoxaban has not yet received pediatric approval. Children with congenital and acquired heart disease (CAHD) constitute a particularly high-risk population for thromboembolic complications due to altered hemodynamics, prosthetic materials, and surgical interventions, necessitating effective anticoagulation strategies. This review summarizes current evidence regarding DOAC use in pediatric CAHD, evaluates safety and efficacy data from recent clinical trials, and highlights key knowledge gaps and future research priorities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.